JPRN-jRCT2031210563招募中3 期
Efficacy and Safety of Tozorakimab (MEDI3506) in Symptomatic Chronic Obstructive Pulmonary Disease With a History of Exacerbations. - OBERO
Ageishi Yuji0 个研究点目标入组 71 人开始时间: 2022年1月19日最近更新:
适应症
试验速览
- 阶段
- 3 期
- 状态
- 招募中
- 发起方
- 入组人数
- 71
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 40age old 至 ot applicable（—）
- 性别
- All
入选标准
- •1. Participant must be 40 years of age or more and capable of giving signed informed consent.
- •2. Documented diagnosis of COPD for at least one year prior to enrolment.
- •3. Post BD FEV1/FVC < 0.70 and post-BD FEV1 >20% of predicted normal value.
- •4. Documented history of 2 or more moderate or 1 or more severe COPD exacerbations within 12 months prior to enrolment.
- •5. Documented optimized inhaled dual or triple therapy at a stable dose for at least 3 months prior to enrolment.
- •6. Smoking history of 10 pack-years or more.
- •7. CAT total score 10 or more, and each of the phlegm (sputum) and cough items 2 or more.
排除标准
- •1. Clinically important pulmonary disease other than COPD.
- •2. Radiological findings suggestive of a respiratory disease other than COPD that is significantly contributing to the participant's respiratory symptoms.
- •3. Current diagnosis of asthma, prior history of asthma, or asthma-COPD overlap. Childhood history of asthma is allowed and defined as asthma diagnosed and resolved before the age of 18.
- •4. Any unstable disorder, including, but not limited to, cardiovascular, gastrointestinal, hepatic, renal, neurological, musculoskeletal, infectious, endocrine, metabolic, haematological, psychiatric disorder, major physical and/or cognitive impairment that could affect
- •safety, study findings or participants ability to complete the study.
- •5. COPD exacerbation, within 2 weeks prior to randomization, that was treated with systemic corticosteroids and/or antibiotics, and/or led to hospitalization.
- •6. Active significant infection within the 4 weeks prior to randomization, pneumonia within 6 weeks prior to randomization, or medical condition that predisposes the participant to infection.
- •7. Suspicion of, or confirmed, ongoing SARS-CoV-2 infection.
- •8. Significant COVID-19 illness within the 6 months prior to enrolment.
- •9. Unstable cardiovascular disorder.
- •10. Diagnosis of cor pulmonale, pulmonary arterial hypertension and/or right ventricular failure.
- •11. History of known immunodeficiency disorder, including a positive test for HIV-1 or HIV 2.
- •12. History of positive test or treatment for hepatitis B or hepatitis C.
- •13. Evidence of active liver disease, including jaundice during screening.
- •14. Malignancy, current or within the past 5 years, except for adequately treated non-invasive basal cell and squamous cell carcinoma of the skin and cervical carcinoma-in-situ treated with apparent success more than one year prior to enrolment. Suspected
- •malignancy or undefined neoplasms.
- •15. Participants who have evidence of active TB.
- •16. Participants that have previously received MEDI3506.
- •17. Any clinically significant abnormal findings in physical examination, vital signs, ECG, or laboratory testing during the screening period, which in the opinion of the investigator may put the participant at risk because of their participation in the study, or may influence the results of the study, or the participant's ability to complete the entire duration of the study.
- •18. Active vaping of any products or using smoked marijuana within the 6 months prior to randomization and during the study.
研究者
相似试验
尚未招募
4 期
Randomized Trial for Comparison between amitriptyline alone and amitriptyline with topiramate combination in chronic migraine ,whether single drug is better or combination of these 2 drugsCTRI/2021/05/033356Principal Investigator Prof Jayantee Kalita
招募中
2 期
Safety of extended use of ModraDoc006/r in patients with advanced solid tumoursAdvanced solid tumoursadvanced solid type of cancer10027655NL-OMON45294Modra Pharmaceuticals BV200
已完成
不适用
Efficacy and Safety of treatment with tocilizumab in refractory patients with Takayasu ArteritisTakayasu arteritisJPRN-UMIN000007845Department of Cardiovascular Medicine Graduate School of Medicine Osaka University15
招募中
2 期
Evaluation of the effectiveness of topiramate in treating dependence of amphetamine and methamphetamine patientsIRCT20160417027437N2Ahvaz University of Medical Sciences60
已完成
3 期
ong-term safety and efficacy of TK-023 in Patients with Severe Dementia of the Alzheimer's TypeDementia of the Alzheimer's typeJPRN-jRCT2080224612TEIKOKU SEIYAKU Co., LTD.70